Enrique Grande, Medical Oncology Department Director at Quironsalud Madrid, Adjunct Professor at The University of Texas MD Anderson Cancer Center, shared a post on X about a paper by Andrea Necchi et al. published in the Journal of Clinical Oncology:
“Refining endpoints for bladder-sparing strategies in MIBC:
An international consensus outlines a unified definition of clinical complete response and reinforces event-free survival as the most reliable primary endpoint for upcoming perioperative trials.”
Title: End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
Authors: Andrea Necchi, Matthew D. Galsky, Nazli Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al-Ahmadie, Andrea B. Apolo, Leslie Ballas, Rick Bangs, Peter C. Black, Maurizio Brausi, Giorgio Brembilla, Liang Cheng, Arturo Chiti, Alessia Cimadamore, Maurizio Colecchia, Siamak Daneshmand, Savino Di Stasi, Jason A. Efstathiou, Alex Filicevas, Daniel M. Geynisman, Petros Grivas, Shilpa Gupta, Alexia Iasonos, Nick D. James, Seth P. Lerner, Yohann Loriot, Lydia E. Makaroff, Fernando Maluf, Marco Moschini, Irina Ostrovnaya, Sumanta K. Pal, Elizabeth R. Plimack, Gagan Prakash, Sarah P. Psutka, Jonathan E. Rosenberg, Sarmad Sadeghi, Bogdana Schmidt, Lawrence H. Schwartz, Guru P. Sonpavde, Marie-Pier St Laurent, Dingwei Ye, Philippe E. Spiess, Ashish M. Kamat
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Enrique Grande.